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Risk of Bladder Cancer among Patients with Diabetes Treated 
with a 15 mg Pioglitazone Dose in Korea: A Multi-Center 
Retrospective Cohort Study
It has not yet been determined whether chronic exposure to relatively low doses of 
pioglitazone increases risk of bladder cancer. We aimed to assess the risk of bladder cancer 
associated with pioglitazone in Korean patients. This was a retrospective cohort study of 
diabetic patients who had ≥ 2 clinic visits between November 2005 and June 2011 at one 
of four tertiary referral hospitals in Korea. A prevalent case-control analysis nested within 
the cohort was conducted to further adjust confounders. A total of 101,953 control 
patients and 11,240 pioglitazone-treated patients were included, in which there were 237 
and 30 cases of incidental bladder cancer (64.9 and 54.9 per 100,000 person-years; age, 
sex-adjusted HR 1.135, 95% confidence interval [CI] 0.769-1.677), respectively. In the 
prevalent case-control analysis nested within the cohort, use of pioglitazone for a duration 
of > 6 months, but not ever use of pioglitazone, was associated with an increased rate of 
bladder cancer as compared to never use of pioglitazone. In conclusion, we failed to 
exclude the possible association between use of pioglitazone for a duration of > 6 months 
and bladder cancer.
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INTRODUCTION 
It has previously been suggested that the use of pioglitazone can increase the risk of 
developing bladder cancer in a dose-response manner (1-5). In addition, several re-
cent meta-analyses also supported this association (6-8). The significance of these me-
ta-analyses, however, was primarily dependent on a large-scale study conducted in a 
French population. Although the French study had sufficient statistical power given its 
large number of study subjects, the data was not adjusted for specific risk factors for 
bladder cancer other than age, sex, and use of glucose-lowering agents (4). The exact 
mechanism of the association between pioglitazone and bladder cancer has not been 
fully understood, although a ‘predisposing’ capacity of peroxisome proliferator-activat-
ed receptor rather than genotoxic or carcinogenic property has been suggested (9-11). 
 In fact, the association between the use of pioglitazone and the risk of developing 
bladder cancer has to date not been definitely demonstrated in an Asian population. 
Interestingly, studies conducted in Taiwanese and Japanese populations have suggest-
ed a non-significant increased risk of developing bladder cancer in short-term users of 
pioglitazone without a dose-dependent relationship (5, 12, 13). Moreover, use of piogl-
itazone at a dosage exceeding 15 mg per day for patients with diabetes has not been 
approved in Korea till 2013. The dosage of up to 15 mg per day is lower than that typi-
cally used in Europe and North America, and it has not yet been determined whether 
chronic exposure to low doses of pioglitazone exhibits a similar risk. 
 We aimed to assess the association between pioglitazone use and the development 
of bladder cancer in a cohort from four tertiary referral hospitals in Korea. 
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MATERIALS AND METHODS
Study subjects
We extracted a clinical database of diabetic patients with two or 
more clinic visits between November 2005 and June 2011 from 
the electronic medical records of four tertiary referral hospitals 
in Korea (Samsung Medical Center, Severance Hospital, Asan 
Medical Center, and Seoul St. Mary’s Hospital, Seoul, Korea). 
Patients were excluded from the study if they had a diagnosis of 
bladder cancer prior to or within three months of the start of 
the study period. 
Definition of exposure and outcome
Use of pioglitazone was defined as receipt of two prescriptions 
for pioglitazone within 6 months of each other during the study 
period. Duration of therapy was calculated according to the in-
terval between the first and last prescriptions. Therefore, the 
duration of therapy was a minimum of the actual duration, as 
additional medication may have been administered by another 
institution prior to visits conducted at the study hospitals. For 
this reason, we conducted a prevalent case-control analysis in 
parallel. In the prevalent case-control analysis, the duration of 
therapy was categorized as never use, ever use, or > 6 months 
based on the minimum actual duration confirmed by review of 
the medical record. Patients with bladder cancer were identi-
fied according to hospital discharge diagnosis (ICD-10 code 
C67).
Prevalent case-control analysis
From the source cohort, all patients with bladder cancer were 
identified. The index date was defined as the date of bladder 
cancer diagnosis. For each patient with a diagnosis of bladder 
cancer, three randomly selected control patients were matched 
according to age (± 1 yr), sex, and the duration between cohort 
entry and either the diagnosis of bladder cancer or the end of 
follow-up (± 3 months). The index date for the controls was the 
date of cohort entry. The risk ratios were estimated from the 
odds ratios obtained from the prevalent case-control analysis, 
based on the rarity-assumption.
Statistical analysis
Comparisons of categorical and continuous variables between 
pioglitazone-treated and control patients were performed using 
chi-square tests and t-tests, respectively. The crude incidence 
rates of bladder cancer for pioglitazone-treated and control pa-
tients were calculated by dividing the number of bladder can-
cer cases by the overall follow-up in terms of person-years. Cox 
proportional hazards models were used to generate adjusted 
hazard ratios (HRs) to compare the incidence rates of bladder 
cancer between pioglitazone-treated and control patients. The 
covariates included age at the time of cohort entry and sex. Cox 
proportional hazards models were constructed for all study sub-
jects. In parallel, a conditional logistic regression was also per-
formed to adjust for potential confounders among the matched 
subjects for prevalent case-control analysis. The confounders 
adopted as covariates in the prevalent case-control analysis in-
cluded smoking status, urinary tract disease or symptoms of a 
urinary tract infection or urolithiasis, duration of diabetes, fast-
ing blood glucose levels, congestive heart failure, estimated 
glomerular filtration rate, history of other malignancy, and anti-
diabetic drugs other than pioglitazone. These were based on 
established conventional parameters that have previously been 
correlated with either bladder cancer or the choice of piogli-
tazone therapy as a part of diabetes treatment. The covariates 
were collected based on the subject’s status at index date on 
medical record. 
Ethics statement
All patients in whom the duration of observation was less than 
three months were also excluded. All study protocols were ap-
proved by the institutional review board (IRB) of each hospital 
that participated in the study (IRB No. 2012-06-083 in Samsung 
Medical Center, No. 4-2011-0646 in Severance Hospital, No. 
2012-0046 in Asan Medical Center, and No. KC12RIMI0037 in 
Seoul St. Mary’s Hospital). Informed consent was waived by the 
IRB.
RESULTS
After exclusion of patients with a diagnosis of bladder cancer 
prior to or within 3-months of entry into the cohort as well as 
patients with a duration of observation of < 3 months, 113,193 
patients with type 2 diabetes were included in this study. Of 
these patients, 11,240 patients had a history of pioglitazone 
treatment (Table 1). 
 A total of 237 (0.23%) and 30 (0.27%) cases of bladder cancer 
Table 1. Demographics of the study cohort according to pioglitazone treatment
Characteristics
Controls
(n = 101,953)
Pioglitazone-treated
(n = 11,240)
P value
Age (yr) 63.4 ± 12.6 62.9 ± 11.7 < 0.001
Sex
Female
Male
47,476 (46.6%)
54,477 (53.4%)
5,364 (47.7%)
5,876 (52.3%)
0.020
Congestive heart failure 3,358 (5.1%) 399 (4.7%) 0.126
Incidental bladder cancer 237 (0.2%) 30 (0.3%) 0.475
Duration of observation
3-6 months
6-12 months
12-24 months
> 24 months
8,208 (8.1%)
13,061 (12.8%)
17,897 (17.6%)
62,787 (61.6%)
478 (4.3%)
752 (6.7%)
1,240 (11.0%)
8,770 (78.0%)
< 0.001
Observed duration of  
   pioglitazone therapy
< 6 months
> 6 months
6,919 (61.6%)
4,321 (38.4%)
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Table 2. Incidence rates of bladder cancer according to pioglitazone treatment
Groups
Bladder cancer 
incidence rate 
(per 100,000 
person-years)
HR (95% CI) adjusted for age and sex 
All study subjects 
(n = 113,193)
Subjects without 
congestive heart 
failure (n = 98,591)
Controls 64.9 Ref. Ref.
Pioglitazone-treated 54.9 1.135 
(0.769-1.677)
1.004 
(0.654-1.542)
Table 3. Baseline characteristics of patients with bladder cancer and matched controls
Characteristics Controls (n = 620) Bladder cancer (n = 208) P value
Age (yr) 69.1 ± 8.8 69.0 ± 8.8 N/A
Male sex 338 (54.5%) 114 (54.8%) N/A
Duration of observation > 24 months 411 (66.3%) 115 (55.3%) N/A
Heart failure 25 (4.0%) 13 (6.3%) 0.178
Duration of diabetes 11.8 ± 9.4 (n = 566) 12.1 ± 10.2 (n = 198) 0.816
Current or ex-smoker 208 (34.0%) 81 (38.9%) 0.155
History of another malignancy 153 (24.9%) 75 (36.1%) 0.002
Benign prostatic hyperplasia 118 (19.0%) 69 (33.2%) < 0.001
Hb 13.0 ± 2.2 (n = 505) 12.4 ± 2.2 (n = 199) 0.007
eGFR 71.3 ± 28.1 (n = 567) 62.0 ± 27.3 (n = 183) < 0.001
Fasting plasma glucose (mg/dL) 137.6 ± 51.5 (n = 592) 153.5 ± 81.6 (n = 196) 0.002
Anti-diabetic drugs other than pioglitazone
Metformin only
Sulfonylurea only
Metformin and sulfonylurea
Any combination including insulin*
Any combination including rosiglitazone
Other drug combinations
49 (8.0%)
47 (7.7%)
72 (11.7%)
176 (28.7%)
50 (8.1%)
220 (35.8%)
16 (7.7%)
22 (10.6%)
16 (7.7%)
76 (36.5%)
23 (11.1%)
55 (26.4%)
0.022
*Excluding patients using rosiglitazone. N/A, not applicable (matching variables); Hb, hemoglobin; eGFR, estimated glomerular filtration rate.
Table 4. Pioglitazone use and the risk of bladder cancer among cases and matched controls
Controls 
(n = 620)
Bladder cancer 
(n = 208)
Crude risk ratio 
(95% confidence interval)
Adjusted risk ratio 
(95% confidence interval)
Never use of pioglitazone 559 (83.4%) 182 (87.5%) 1 (reference) 1 (reference)
Ever use of pioglitazone 61 (9.8%) 26 (12.5%) 1.319 (0.800-2.175) 1.353 (0.748-2.445)
Use of pioglitazone for > 6 months 39 (6.5%) 22 (10.8%) 1.832 (1.033-3.248) 1.969 (1.020-3.802)
were identified in control and pioglitazone-treated subjects dur-
ing the follow-up period of 370,620 and 54,650 person-years, 
respectively. The incidence rate of bladder cancer per 100,000 
person-years was 64.9 and 54.9 in control and pioglitazone-
treated subjects, respectively (Table 2). Use of pioglitazone use 
was not significantly associated with the incidence of bladder 
cancer (age, sex-adjusted HR 1.135, 95% confidence interval 
[CI] 0.769-1.677). 
 To further adjust confounders other than age and sex, a prev-
alent case-control analysis nested within the cohort was con-
ducted. In this analysis, the duration of pioglitazone treatment 
was re-defined based on a detailed review of the medical re-
cord. Cases with bladder cancer (n = 208) were matched to 620 
control subjects based on their age, sex, and the duration of ob-
servation in the source cohort. On univariate analysis, a history 
of another malignancy, benign prostatic hyperplasia, low he-
moglobin, low estimated glomerular filtration rate (eGFR), and 
high fasting plasma glucose were associated with bladder can-
cer (Table 3). Based on these results, congestive heart failure, 
duration of diabetes, smoking status, history of another malig-
nancy, benign prostatic hyperplasia, hemoglobin level, eGFR, 
fasting plasma glucose (mg/dL), and anti-diabetic drugs other 
than pioglitazone were included in the multivariate analysis us-
ing conditional logistic regression analysis for covariates. In this 
analysis, use of pioglitazone for a duration of > 6 months, but 
not ever use, was associated with an increased incidence rate of 
bladder cancer (adjusted rate ratio 1.969; 95% CI, 1.020-3.802; 
Table 4).
 
DISCUSSION
In our multi-center hospital-based cohort (n = 113,193), the in-
cidence of bladder cancer was similar to those in the previous 
population-based studies (1, 2, 4, 5). Although increase in blad-
der cancer incidence in pioglitazone-treated patients was not 
significant in Cox regression analysis, there was an association 
between > 6 months of pioglitazone therapy and an increased 
risk of bladder cancer in the prevalent case-control analysis 
nested within the cohort in which confounders other than age 
and sex were adjusted and the duration of pioglitazone was re-
defined.
 No significant association between pioglitazone use and blad-
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der cancer found on Cox regression analysis in this study is not 
surprising, because most previous studies including the studies 
conducted in the Kaiser Permanente Northern California (KPNC) 
cohort (2) and the Taiwanese cohort (5) did not demonstrated 
the significance of association between ever use of pioglitazone 
and increased incidence of bladder cancer. In the KPNC cohort, 
a significant association between pioglitazone use and bladder 
cancer was identified only after a detailed dose-response analy-
sis (2). Notably, the significant association between ever use of 
pioglitazone therapy and the risk of bladder cancer in recent 
meta-analyses was primarily based on the results of large-scale 
French study (4, 6). In addition, the hazard ratio of Cox regres-
sion in this study could be underestimated because the study 
subjects in this study was not restricted to newly-diagnosed di-
abetes patients and the exposure definition did not include the 
use of pioglitazone outside the four hospitals included in this 
study. Therefore, the results of Cox regression in this study is 
not in contrast to the association between pioglitazone expo-
sure and bladder cancer suggested by the previous studies, be-
cause the available evidence of such association to date was 
mostly from the delicate dose-response analysis rather than the 
comparison of ever and never use (1-3, 12). For this reason, we 
additionally conducted a prevalent case-control analysis nested 
within the source cohort to further adjust the confounders and 
to re-define the treatment duration of pioglitazone based on a 
detailed review of medical records. 
 Although no significant association between pioglitazone 
use and bladder cancer was found on Cox regression analysis 
in this study, we did observe a significant association in our 
prevalent case-control analysis when the observed duration of 
treatment was > 6 months. The additional analysis of the sub-
jects with > 6 months of pioglitazone treatment was performed 
primarily because most of the previous large scale cohort stud-
ies excluded patients with an observed duration of treatment 
< 6 months in order to exclude cases of latent bladder cancer 
that were not identified until the initiation of pioglitazone ther-
apy (2, 4). 
 Although there have been multiple large-scale cohort studies 
that have described a dose-dependent relationship between 
pioglitazone and the risk of bladder cancer, most of this evidence 
was obtained from European and North American populations 
(1-3, 12). In a Taiwanese cohort, this dose-dependent relation-
ship was not observed, as the majority of bladder cancer cases 
in pioglitazone users were found in those that underwent short-
term therapy (5). A case-control study in Japan also suggested 
an association between the use of pioglitazone for < 24 months 
and the risk of bladder cancer, while the overall hazard ratio 
was not significant (13). Additionally, in our preliminary case-
control study conducted in patients at a single university hospi-
tal, a dose-dependent relationship was not identified (14). Al-
though the delicate dose-response analysis was impossible, our 
results suggest that an association between long-term use of pi-
oglitazone and the risk of bladder cancer cannot be excluded in 
the Korean population, given that patients treated with piogli-
tazone for > 6 months in the current study are likely to have a 
longer actual duration of therapy. 
 Several limitations of the current study should also be noted, 
however. First, this is not a population-based study. Therefore, 
our conclusions should not be applied in the primary care set-
ting in which the risk profile of the patient population for the 
bladder cancer may be different. Secondly, we were unable to 
analyze the exact duration and cumulative dose of pioglitazone 
due to our limited access to health information outside of the 
records from the four tertiary hospitals that participated in this 
study. Thirdly, subjects with bladder cancer in this study showed 
significantly higher frequencies of other malignancy, benign 
prostate hyperplasia, anemia, decreased renal function, and in-
sulin resistance, and more insulin users, suggesting that worse 
medical condition even they were not older or male predomi-
nant. Therefore, the results could be biased by these factors, al-
though we used these variables as covariates for multiple logis-
tic analysis.
 In conclusion, we failed to exclude the possible association 
between use of a 15 mg pioglitazone dose for a duration of > 6 
months and bladder cancer, although increase in bladder can-
cer incidence in pioglitazone-treated patients was not signifi-
cant in Cox regression analysis. Until the results of a popula-
tion-based study with a delicate dose-response analysis in Ko-
reans are available, clinicians should carefully monitor the pos-
sible development of bladder cancer and consider the risk-to-
benefit ratio before starting pioglitazone therapy in high risk 
patients.
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